Free Trial

Intellia Therapeutics (NTLA) News Today

→ It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad)
Free NTLA Stock Alerts
$22.73
-0.22 (-0.96%)
(As of 06/7/2024 08:52 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 9 at 6:20 AM | fool.com
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
June 8 at 7:16 PM | marketbeat.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Seven Eight Capital LP
Seven Eight Capital LP lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 219.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 61,192 shares of the company's stock after purchasing an
June 8 at 7:25 AM | fool.com
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
June 7 at 10:32 PM | marketbeat.com
Sectoral Asset Management Inc. Cuts Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Sectoral Asset Management Inc. lowered its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 91.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,300 shares of the company's stock aft
June 6, 2024 | fool.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
June 6, 2024 | americanbankingnews.com
Intellia Therapeutics (NASDAQ:NTLA) Trading 2.4% Higher
June 6, 2024 | americanbankingnews.com
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Reaffirmed by Cantor Fitzgerald
June 5, 2024 | investorplace.com
The 3 Best Biotech Stocks to Buy in June 2024
June 5, 2024 | marketbeat.com
Rafferty Asset Management LLC Purchases 77,873 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Rafferty Asset Management LLC lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 31.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 328,998 shares of the comp
June 5, 2024 | seekingalpha.com
Intellia Therapeutics Presents Promising In Vivo CRISPR Results
June 4, 2024 | marketbeat.com
Intellia Therapeutics (NASDAQ:NTLA) Receives Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Intellia Therapeutics in a research note on Tuesday.
June 4, 2024 | marketbeat.com
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 2.4%
Intellia Therapeutics (NASDAQ:NTLA) Shares Up 2.4%
June 4, 2024 | fool.com
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
June 4, 2024 | marketbeat.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by UBS Group AG
UBS Group AG lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 121.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 274,524 shares of the company's stock after purchasing an additional 150,
June 3, 2024 | insidermonkey.com
Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) the Most Promising Gene Therapy Stock to Buy Now?
June 3, 2024 | marketbeat.com
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up to $21.38
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up to $21.38
June 2, 2024 | globenewswire.com
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
June 1, 2024 | marketbeat.com
Dimensional Fund Advisors LP Raises Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Dimensional Fund Advisors LP grew its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,170,829 shares of the company's stock after purchasing an additio
June 1, 2024 | americanbankingnews.com
Intellia Therapeutics, Inc. Expected to Post FY2024 Earnings of ($4.50) Per Share (NASDAQ:NTLA)
May 31, 2024 | marketbeat.com
FY2024 EPS Estimates for Intellia Therapeutics, Inc. Increased by Chardan Capital (NASDAQ:NTLA)
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Research analysts at Chardan Capital increased their FY2024 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a research note issued to investors on Tuesday, May 28th. Chardan Capital analyst Y. Livshits now expects
May 28, 2024 | marketbeat.com
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 3.6%
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 3.6%
May 22, 2024 | fool.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
May 17, 2024 | marketbeat.com
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Nikko Asset Management Americas Inc.
Nikko Asset Management Americas Inc. cut its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,478,562 shares of the company's stock
May 14, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Iovance Biotherapeutics (IOVA) and Intellia Therapeutics (NTLA)
May 13, 2024 | marketbeat.com
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 8.5% After Analyst Upgrade
Intellia Therapeutics (NASDAQ:NTLA) Trading 8.5% Higher on Analyst Upgrade
May 13, 2024 | seekingalpha.com
Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 12, 2024 | finance.yahoo.com
Earnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 11, 2024 | marketbeat.com
Intellia Therapeutics (NASDAQ:NTLA) Raised to "Sell" at StockNews.com
StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a research report on Friday.
May 10, 2024 | marketbeat.com
Intellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $29.00 at Citigroup
Citigroup cut their price target on Intellia Therapeutics from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Friday.
May 10, 2024 | markets.businessinsider.com
Barclays Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
May 10, 2024 | marketbeat.com
BMO Capital Markets Raises Intellia Therapeutics (NASDAQ:NTLA) Price Target to $70.00
BMO Capital Markets lifted their target price on Intellia Therapeutics from $62.00 to $70.00 and gave the company an "outperform" rating in a report on Friday.
May 10, 2024 | fool.com
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
May 10, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
May 10, 2024 | finance.yahoo.com
Intellia Therapeutics First Quarter 2024 Earnings: Beats Expectations
May 9, 2024 | msn.com
NTLA Stock Earnings: Intellia Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 9, 2024 | marketbeat.com
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up to $23.00
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up to $23.00
May 9, 2024 | finanznachrichten.de
Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 9, 2024 | seekingalpha.com
Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 9, 2024 | globenewswire.com
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 5, 2024 | marketbeat.com
265,981 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by Vestmark Advisory Solutions Inc.
Vestmark Advisory Solutions Inc. bought a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 265,981 shares of the company's stock, valued at approximately $8,110,000. Vest
May 3, 2024 | investorplace.com
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar
May 3, 2024 | marketbeat.com
Intellia Therapeutics (NTLA) Set to Announce Quarterly Earnings on Thursday
Intellia Therapeutics (NASDAQ:NTLA) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.
May 3, 2024 | investing.com
Intellia Therapeutics Inc (NTLA) Earnings Dates & Reports
May 2, 2024 | finance.yahoo.com
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
May 2, 2024 | globenewswire.com
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
May 2, 2024 | investorplace.com
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
April 30, 2024 | seekingalpha.com
Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
April 29, 2024 | marketbeat.com
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 6.8%
Intellia Therapeutics (NASDAQ:NTLA) Shares Up 6.8%
April 29, 2024 | globenewswire.com
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
April 28, 2024 | marketbeat.com
abrdn plc Buys New Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
abrdn plc bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 154,269 shares of the company's stock, valued at approximately $4,704,000. abrd
Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

It's time to ween off Chinese lithium! (Ad)

As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely

Learn how this American company is leading the lithium-ion revolution

NTLA Media Mentions By Week

NTLA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NTLA
News Sentiment
▼
0.83

0.77
▲
Average
Medical
News Sentiment

NTLA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NTLA Articles
This Week
▼
17

4
▲
NTLA Articles
Average Week

Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:NTLA) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
Alert: Your Bank is Dying – Act Now or Lose Everything!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...
Priority Gold | Sponsored
It's time to ween off Chinese lithium!
As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...
Smallcaps Daily | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Hurry! Buy this stock before the Robinhood traders do!
Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...
Traders Agency | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored